about
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.Testicular sex cord-stromal tumours: the Edinburgh experience 1988-2002, and a review of the literature.Neoadjuvant chemotherapy in transitional-cell carcinoma of the bladder.Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.Cyborgs in the Everyday: Masculinity and Biosensing Prostate CancerA randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK).Translational research will fail without surgical leadership: SCOTRRCC a successful surgeon-led Nationwide translational research infrastructure in renal cancer.Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.INVITED REVIEW--IMAGE REGISTRATION IN VETERINARY RADIATION ONCOLOGY: INDICATIONS, IMPLICATIONS, AND FUTURE ADVANCES.Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions.Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).Identifying the dominant prostate cancer focal lesion using image analysis and planning of a simultaneous integrated stereotactic boost.The Importance of Prostate-specific Antigen (PSA) Nadir and Early Identification of PSA Relapse after 10 Years of Prostate Iodine 125 Seed Brachytherapy in Edinburgh.Identifying radiotherapy target volumes in brain cancer by image analysis.Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.Clinically relevant fatigue in recurrence-free prostate cancer survivors.Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy.Targeted SERS nanosensors measure physicochemical gradients and free energy changes in live 3D tumor spheroids.Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.Characterisation of radiotherapy planning volumes using textural analysis.Image-guided radiotherapy of bladder cancer: bladder volume variation and its relation to margins.Measuring the effects of fractionated radiation therapy in a 3D prostate cancer model system using SERS nanosensorsEPID-based in vivo dosimetry using Dosimetry Check™: Overview and clinical experience in a 5-yr study including breast, lung, prostate, and head and neck cancer patientsThe comet assay in clinical practiceImpact of nicotinamide on human tumour hypoxic fraction measured using the comet assayTreatment margins and treatment fractionation in conformal radiotherapy of muscle-invading urinary bladder cancerA concomitant tumour boost in bladder irradiation: patient suitability and the potential of intensity-modulated radiotherapyA long and winding road: the role of chemotherapy for hormone-refractory prostate cancerOutcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapyStereotactic body radiotherapyRadiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy
P50
Q35319155-C018BB22-5F8B-44B4-A425-F209822DCE21Q36081868-E50D99DD-BE3B-491B-A452-B645A65089D0Q36227803-254E4571-155F-4E84-9797-9FA9C1BB0ADFQ36292060-80AA065D-29A2-4F3F-92CF-B0940E9E4B32Q36707077-C10C3DDB-A5CC-4590-94DA-CB3DF8E2218DQ36971860-C6A92AB9-5A03-4DA3-A0BE-7F1C7C66E995Q38382541-DCA28D76-7C20-4CE1-9DDD-B02A5CBF6A72Q38390224-9093B27F-7EB7-43B1-A1E9-AEE59DEE39FAQ38396913-FBC1B40C-2425-4D1E-A07A-6E266BD7C3C5Q38699968-D9667DF6-DBB3-4827-AFC1-EBC565EB06FEQ39459344-71FB0959-F8CA-4633-8FD5-2CF07BD793B1Q39648965-D8A3411E-E373-4E06-9E47-2B77FB24322AQ39714017-390F8C7E-A201-42F5-9B03-B50EA277B03CQ40511771-B7A2C48C-12DD-4F4C-9C6D-59C7075FA55BQ40817423-01950370-2E01-4222-B09D-618110F517F9Q42603673-2ED893C4-270C-4500-9FED-84FE9BD8CAB1Q43756593-D164B04C-DEC1-42BF-BAA3-933FCF7C6BD7Q45767001-BDACDC75-E5F6-48C2-9C36-A682A83A2839Q48566919-8AA37411-9D70-435A-B68D-3F0DD8E8516AQ51142915-080D6895-3A4E-4F54-87AB-A1F36D290238Q52660703-EF1F2B95-AB63-4FD6-8B05-24E19ADCC96FQ53401384-560838D4-D01E-449F-9123-7800FF766548Q53469021-98BF8542-EBF4-4EAA-B81B-2EAF7CC368F6Q57155698-D7D78630-2129-423F-8540-D51048BCA1C3Q61450611-4000C6D5-FC29-4A7F-8845-2D9B7C26D2FEQ73292668-1849D231-E15B-46B6-957F-D5B0A2756DD7Q74019861-8488F1B3-804D-455E-8E8F-E5497E267676Q79878284-2EA0D978-8CA3-4135-AC5E-44791170E8BBQ80021039-23940CAF-72C2-43FF-A7E6-162E42D1416CQ81588830-02E0EC42-BD01-43AC-91A4-7B78B4C8001FQ83915029-B53F7687-FA23-4A1C-B156-CCE2B2E900F7Q86842168-CA16583E-C992-4E88-A0FB-ACAA0888D305Q91436407-A5EDFE6D-A90A-40A1-8845-358156109873
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Duncan McLaren
@ast
Duncan McLaren
@en
Duncan McLaren
@es
Duncan McLaren
@nl
Duncan McLaren
@sl
type
label
Duncan McLaren
@ast
Duncan McLaren
@en
Duncan McLaren
@es
Duncan McLaren
@nl
Duncan McLaren
@sl
prefLabel
Duncan McLaren
@ast
Duncan McLaren
@en
Duncan McLaren
@es
Duncan McLaren
@nl
Duncan McLaren
@sl
P106
P108
P1153
7101974080
P31
P496
0000-0002-9862-4158